COMMUNIQUÉS West-GlobeNewswire

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
30/06/2025
Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz ® and RhodoLED ® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG. Under their new [...]
SPR Receives Fourth Consecutive Northeast Ohio Top Workplaces Award
30/06/2025
- Based on employee feedback highlighting strong corporate culture - CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- For the fourth year in a row, SPR has been recognized as a Top Workplace by Northeast Ohio Top Workplaces [...]
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
30/06/2025
– Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b studies for ABI- [...]
Synergy CHC Corp. (NASDAQ: SNYR) Secures Landmark Retail and Distribution Wins Across North America for FOCUSfactor Supplements and Functional Beverages
30/06/2025
Core-Mark National Authorization, Walmart Canada Breakthrough, and Key Regional Wins Highlight Rapid Growth in Functional Beverage and Supplement Categories WESTBROOK, Maine, June 30, 2025 (GLOBE NEWSWIRE) -- Synergy [...]
IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period
30/06/2025
LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in consultation with The [...]
Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions
30/06/2025
Er-Kim will distribute KIMMTRAK® (tebentafusp) for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, in accordance with applicable local regulations in the agreed regions [...]
CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025
30/06/2025
ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, has been named [...]
Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement
30/06/2025
Increases total holdings to 1,306,452 HYPE LAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly [...]
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation
30/06/2025
SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. [...]
Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet-AMD at 2025 MaculArt Meeting
30/06/2025
Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD Novel subcutaneous delivery may offer a more patient-friendly alternative to [...]
Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study
30/06/2025
Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with [...]
Microbot Medical® Added to the Russell Microcap® Index
30/06/2025
Automatic inclusion in the appropriate growth and value style indexes HINGHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic [...]
Clover Health Set to Join Russell 3000® Index
30/06/2025
WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market [...]
EVA Pharma and Zhejiang Jinhua CONBA Bio-Pharm Sign Strategic Supply Agreement
30/06/2025
Two Regional Powerhouses to Strengthen Cross-Border Collaboration for a More Resilient and Accessible Healthcare Supply Chain SHANGHAI and CAIRO, June 30, 2025 (GLOBE NEWSWIRE) -- EVA Pharma , one of the leading [...]
Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis
30/06/2025
The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously reported two [...]
INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute
30/06/2025
MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, is excited to announce [...]
GCANRx Announces Uplisting to New Market Tier
30/06/2025
BALTIMORE, June 30, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and [...]
Senti Bio Participates in Nasdaq Amplify Spotlight Series
30/06/2025
Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next- [...]
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
30/06/2025
Vancouver, Canada, June 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]

Pages